AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 40.21 |
Market Cap | 3.18B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.13 |
PE Ratio (ttm) | -315.23 |
Forward PE | n/a |
Analyst | Buy |
Ask | 45 |
Volume | 501,770 |
Avg. Volume (20D) | 760,280 |
Open | 43.09 |
Previous Close | 42.78 |
Day's Range | 40.25 - 43.52 |
52-Week Range | 18.61 - 46.00 |
Beta | undefined |
About VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...
Analyst Forecast
According to 7 analyst ratings, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 2.49% from the latest price.
Next Earnings Release
Analysts project revenue of $115.07M, reflecting a 17.18% YoY growth and earnings per share of 0.05, making a 0.00% YoY.
2 months ago · seekingalpha.com
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call TranscriptVeracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
3 months ago · businesswire.com
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 ...